Clinical Pharmacokinetics and Pharmacodynamics of Naloxone
Open accessThe DOI matches its Crossref record; 154 of the 154 references it cites were found in a registry or an index.
Abstract
Naloxone is a World Health Organization (WHO)-listed essential medicine and is the first choice for treating the respiratory depression of opioids, also by lay-people witnessing an opioid overdose. Naloxone acts by competitive displacement of opioid agonists at the μ-opioid receptor (MOR). Its effect depends on pharmacological characteristics of the opioid agonist, such as dissociation rate from the MOR receptor and constitution of the victim. Aim of treatment is a balancing act between restoration of respiration (not consciousness) and avoidance of withdrawal, achieved by titration to response after initial doses of 0.4–2 mg. Naloxone is rapidly eliminated [half-life ( t 1/2 ) 60–120 min] due to high clearance. Metabolites are inactive. Major routes for administration are intravenous, intramuscular, and intranasal, the latter primarily for take-home naloxone. Nasal bioavailability is about 50%. Nasal uptake [mean time to maximum concentration ( T max ) 15–30 min] is likely slower than intramuscular, as reversal of respiration lag behind intramuscular naloxone in overdose victims. The intraindividual, interindividual and between-study variability in pharmacokinetics in volunteers are large. Variability in the target population is unknown. The duration of action of 1 mg intravenous (IV) is 2 h, possibly longer by intramuscular and intranasal administration. Initial parenteral doses of 0.4–0.8 mg are usually sufficient to restore breathing after heroin overdose. Fentanyl overdoses likely require higher doses of naloxone. Controlled clinical trials are feasible in opioid overdose but are absent in cohorts with synthetic opioids. Modeling studies provide valuable insight in pharmacotherapy but cannot replace clinical trials. Laypeople should always have access to at least two dose kits for their interim intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Time course (left: 0–240 min, right: 0–60 min) of plasma concentrations of intravenous and intramuscular naloxone (0.4 mg) and concentrated intranasal formulations of 1, 2, and 4 mg naloxone. Note the initial closeness of serum concentrations of the regulatory golden standard 0.4 mg intramuscular dose and the 2 mg intranasal dose. Note also that plasma concentrations after 2 mg intranasal naloxone surpass that of 0.4 mg intramuscular naloxone after 6 min and stay above that of intramuscular for the remaining 120 min. Also, note the dramatic overshoot by the 4 mg dose compared with the 0.4 mg intramuscular dose. Redrawn from McDonald et al. [83] with permission](https://figures.cochat.ai/paper-figures/af98393d605c4f64b63e2642619cc2eb/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-2.jpg)
![Fig. 3 Dose–concentration linearity for maximum serum concentration (Tmax) and area under the curve (AUC) after nasal spraying of 0.8–2.0 mg of concentrated nasal naloxone formulations in healthy volunteers (compiled from two different studies [48, 62] with the same formulation). This linearity is the scientific basis for a two-dose administration by laypeople in take-home naloxone (THN)](https://figures.cochat.ai/paper-figures/8d8ad05c57804a1cb930ebc329e3741c/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-3.jpg)
![Fig. 4 Inter- and intraindividual variability of the absolute bioavailability of intranasal naloxone [AUC(IN)/AUC(IV) × DOSE(IV)/DOSE(IN)] based on AUC0−inf in 22 healthy volunteers. Not only does the absolute nasal bioavailability vary from about 20% to almost 100% between individuals but also is usually reproduced in an individual. Similar findings were observed for the relative intranasal to intramuscular bioavailability in the same subjects [19]](https://figures.cochat.ai/paper-figures/60c0086d84d04aa1a3816c462545ec6c/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-4.jpg)
![Fig. 5 Time course of pupil diameter in healthy volunteers exposed to remifentanil and naloxone [n = 12, mean (95% confidence interval)]. Remifentanil was started at t = −12 min and stopped at t = 90 min (orange, horizontal line). Miosis was rapidly reversed by a naloxone bolus of 1 mg intravenously given at t = 0. The blue broken line is the regression line [f(x) = − 0.0292x + 6.9924)] and is based on the period 19–89 min. It crosses the nadir baseline (black dotted line) at 118 min. The blood concentration of naloxone at this point was 0.5 ng/ml, which is the minimum effective concentration of naloxone in steady state. Redrawn from Tylleskar et al. [63] with permission](https://figures.cochat.ai/paper-figures/578f4a8864ce412a8c8ee73b51100f6f/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-5.jpg)
![Fig. 6 Hysteresis plot of pupil diameter and naloxone concentration during a remifentanil infusion with stable blood concentrations (see legend for Fig. 5). The red line represents arterial samples, and the blue line represent venous samples. The direction of time is illustrated by the arrow. This finding allows for the use of venous concentrations in PK/PD modeling. Redrawn from Tylleskar et al. [63] with permission](https://figures.cochat.ai/paper-figures/b220aa8ae742457b8a62ffa4a663d065/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-6.jpg)
![Fig. 7 Simulated time courses of mean naloxone concentrations (lines) and standard deviations as shaded areas: 0.8 mg intramuscular (dark gray), 0.4 mg intramuscular (light gray), and 1.4 mg intranasal (blue). Time of administration of injected naloxone is t = 0 min. A Intranasal 1.4 mg administered 10 min prior to injected naloxone (0.4 and 0.8 mg). B Simulation of the shortest time (2.25 min) beneficial to administer the intranasal spray, rather than wait for naloxone to be injected by medical personnel. C Simulation of 1.4 mg intranasal naloxone when intramuscular 0.4 mg naloxone is injected to a patient 10 min before the intranasal dose. Redrawn from Skulberg et al. [77]](https://figures.cochat.ai/paper-figures/e36c40238a254694b601924d47af563e/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-7.jpg)
![Fig. 8 Simulated concentration–time profiles of plasma naloxone after various common clinical dosing schemes in opioid overdose. A pharmacokinetic model based on our own data and 1000 simulations were used (Anesthesiology, manuscript in review) [108]. Two intravenous (0.4 and 2 mg, shown in gray and black, respectively) and three intramuscular doses (0.4, 0.8, and 2.0 mg, shown in light blue, yellow and blue, respectively) were simulated using the final pharmacokinetic model. The lower dotted line suggests the duration of action, represented by an experimentally determined minimum effective concentration of 0.5 ng/ml [76] and the upper dotted line suggests an increased risk of withdrawal, represented by the Cmax (3.2 ng/ml) and 0.8 mg intramuscular dose [18, 109]](https://figures.cochat.ai/paper-figures/85677e99c40a46719425a695c6f3385b/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-8.jpg)
![Fig. 9 Simulated plasma concentration profiles after single bolus doses (0.9, 1.4, 2.0, or 4.0 mg) of intranasal naloxone, alone or with remifentanil dosing (A and B, respectively) using a pharmacokinetic model based on our own data (Anesthesiology, manuscript in review) [108]. Plasma concentration–time course of the regulatory golden standard, an intramuscular 0.4 mg bolus dose, is shown in blue](https://figures.cochat.ai/paper-figures/c080496a8e7b45d281e0d6f2b31e4458/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-9.jpg)
![Fig. 10 A randomized, double-blinded comparison of naloxone given intramuscularly (0.8 mg, blue) or intranasally (1.4 mg, brown) by the ambulance service in opioid overdose (n = 201) Shaded areas represent 95% confidence interval. Kaplan–Meier plot showing the probability of not having reached satisfactory respiration (10 breaths/min). Curves are similar until 3 min, and the restoring of respiration is 2.3 min slower after the intranasal dose at 10 min. In real life, this difference is probably smaller, as intranasal administration is likely faster to complete than intramuscular. These intoxications were also more serious than those in an unselected material in the same catchment area [110]. Redrawn from Skulberg et al. [73]](https://figures.cochat.ai/paper-figures/dac41243484b4e5ab028ddedcda09040/clinical-pharmacokinetics-and-pharmacodynamics-of-naloxone-figure-10.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, interindividual tolerance to different opioids varies greatly from opioid-naive patients to patients who use opioids regularly.”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [47]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nitazene’s high potency and activation at the mu opioid receptor allows for naloxone reversal through competitive antagonism at this exact receptor [36].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early naloxone administration remains critical because reversal of opioid respiratory depression reduces the mortality risk of these drugs [36].”
From Novel 2-Benzylbenzimidazole Opioids: Emerging Drugs of Abuse and Pharmacological Considerations with Nitazene Analogs (2026) · cites this paper as [36]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“This is highlighted for morphine, as its serum concentrations were significantly higher in patients receiving intravenous morphine for cancer-related pain than in all morphine-positive post-mortem cases in another study [14,47].”
From Nitazenes: review of comparative pharmacology and antagonist action (2025) · cites this paper as [47]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arzneimittelforschung: Erstanwendung am Menschen in der Phase I
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt Gesundheitsforsch.Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,355
Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and Children
Kearns, G. L., Abdel-Rahman, S. M., Alander, S. W., Blowey, D. L., Leeder, J. S., & Kauffman, R. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035092 · Cited by 2,421
Mould, D., & Upton, R. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.14 · Cited by 897
Management of Opioid Analgesic Overdose
Boyer, E. W. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1202561 · Cited by 605
Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development
Mould, D., & Upton, R. (2012) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2012.4 · Cited by 544
EEG Quantitation of Narcotic Effect: The Comparative Pharmacodynamics of Fentanyl and Alfentanil
Scott, J. C., Ponganis, K. V., & Stanski, D. R. (1985) · Anesthesiology · doi:10.1097/00000542-198503000-00005 · Cited by 492
McDonald, R., & Strang, J. (2016) · Addiction · doi:10.1111/add.13326 · Cited by 471
Self-citationNaloxone dosage for opioid reversal: current evidence and clinical implications
Rzasa Lynn, R., & Galinkin, J. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617744161 · Cited by 346
Pharmacokinetics of Naloxone in Rats and in Man: Basis for Its Potency and Short Duration of Action
Ngai, S. H., Berkowitz, B. A., Yang, J. C., Hempstead, J., & Spector, S. (1976) · Anesthesiology · doi:10.1097/00000542-197605000-00008 · Cited by 287
Nasal administration of opioids for pain management in adults
Dale, O., Hjortkjær, R., & Kharasch, E. D. (2002) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2002.460702.x · Cited by 270
Self-citationUpton, R., & Mould, D. (2014) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.71 · Cited by 265
Imaging Opiate Receptors in the Human Brain by Positron Tomography
Frost, J. J., Wagner, H. N., Dannals, R. F., Ravert, H. T., Links, J. M., Wilson, A. A., Burns, H. D., Wong, D. F., McPherson, R. W., Rosenbaum, A. E., et al. (1985) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-198503000-00001 · Cited by 249
The Relationship of Pharmacokinetics to Pharmacological Activity: Morphine, Methadone and Naloxone
Berkowitz, B. A. (1976) · Clinical Pharmacokinetics · doi:10.2165/00003088-197601030-00004 · Cited by 239
Fentanyl depression of respiration: Comparison with heroin and morphine
Hill, R., Santhakumar, R., Dewey, W., Kelly, E., & Henderson, G. (2020) · British Journal of Pharmacology · doi:10.1111/bph.14860 · Cited by 216
Kiyatkin, E. A. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.008 · Cited by 192
Naloxone in opioid poisoning: walking the tightrope
Clarke, S. F. J. (2005) · Emergency Medicine Journal · doi:10.1136/emj.2003.009613 · Cited by 190
Rook, E., Huitema, A., Brink, W., Ree, J., & Beijnen, J. (2006) · Current Clinical Pharmacology · doi:10.2174/157488406775268219 · Cited by 189
The expanding role of quantitative structure-activity relationships (QSAR) in toxicology
Hansch, C., Hoekman, D., Leo, A., Zhang, L., & Li, P. (1995) · Toxicology Letters · doi:10.1016/0378-4274(95)03356-p · Cited by 188
Kerr, D., Kelly, A., Dietze, P., Jolley, D., & Barger, B. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02724.x · Cited by 175
Heroin overdose: the case for take-home naloxone
Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R. (1996) · BMJ · doi:10.1136/bmj.312.7044.1435 · Cited by 172
Self-citationTam, S. W. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90536-9 · Cited by 172
Adverse events after naloxone treatment of episodes of suspected acute opioid overdose
Buajordet, I., Næss, A.-C., Jacobsen, D., & Brørs, O. (2004) · European Journal of Emergency Medicine · doi:10.1097/00063110-200402000-00004 · Cited by 167
Wermeling, D. P. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098614564776 · Cited by 164
Kelly, A., Kerr, D., Koutsogiannis, Z., Dietze, P., Patrick, I., & Walker, T. (2005) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2005.tb06550.x · Cited by 164
Torralva, R., & Janowsky, A. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.258566 · Cited by 159
The Effect of Overdose Education and Naloxone Distribution: An Umbrella Review of Systematic Reviews
Razaghizad, A., Windle, S. B., Filion, K. B., Gore, G., Kudrina, I., Paraskevopoulos, E., Kimmelman, J., Martel, M. O., & Eisenberg, M. J. (2021) · American Journal of Public Health · doi:10.2105/ajph.2021.306306 · Cited by 159
DISPOSITION OF NALOXONE-7,8-3H IN NORMAL AND NARCOTIC-DEPENDENT MEN
Fishman, J., Roffwarg, H., & Hellman, L. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29707-5 · Cited by 144
Fatal Fentanyl: One Pill Can Kill
Sutter, M. E., Gerona, R. R., Davis, M. T., Roche, B. M., Colby, D. K., Chenoweth, J. A., Adams, A. J., Owen, K. P., Ford, J. B., Black, H. B., et al. (2017) · Academic Emergency Medicine · doi:10.1111/acem.13034 · Cited by 144
Barton, E. D., Colwell, C. B., Wolfe, T. R., Fosnocht, D., Gravitz, C. S., Bryan, T. S., Dunn, W., Benson, J., & Bailey, J. E. (2005) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2005.03.007 · Cited by 142
Fogarty, M. F., Papsun, D. M., & Logan, B. K. (2018) · Journal of Analytical Toxicology · doi:10.1093/jat/bky035 · Cited by 136
The anomalous pharmacology of fentanyl
Kelly, E., Sutcliffe, K., Cavallo, D., Ramos‐Gonzalez, N., Alhosan, N., & Henderson, G. (2023) · British Journal of Pharmacology · doi:10.1111/bph.15573 · Cited by 136
Disposition of naloxone: use of a new radioimmunoassay.
Berkowitz, B. A., Ngai, S. H., Hempstead, J., & Spector, S. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30367-8 · Cited by 135
Naloxone Reversal of Buprenorphine-induced Respiratory Depression
van Dorp, E., Yassen, A., Sarton, E., Romberg, R., Olofsen, E., Teppema, L., Danhof, M., & Dahan, A. (2006) · Anesthesiology · doi:10.1097/00000542-200607000-00012 · Cited by 129
A dosing nomogram for continuous infusion intravenous naloxone
Goldfrank, L. R., Weisman, R. S., Errick, J. K., & Lo, M.-W. (1986) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(86)80994-5 · Cited by 128
Strang, J., McDonald, R., Campbell, G., Degenhardt, L., Nielsen, S., Ritter, A., & Dale, O. (2019) · Drugs · doi:10.1007/s40265-019-01154-5 · Cited by 127
Self-citationCould chest wall rigidity be a factor in rapid death from illicit fentanyl abuse?
Burns, G., DeRienz, R. T., Baker, D. D., Casavant, M., & Spiller, H. A. (2016) · Clinical Toxicology · doi:10.3109/15563650.2016.1157722 · Cited by 126 · cited 4×
“It is important to note that naloxone also reverses muscle rigidity associated with overdose with fentanyl and its analogues [101, 105, 107], although possibly not vocal cord closure [106].”
BackgroundInfluentialFentanyl-Induced Chest Wall Rigidity
Çoruh, B., Tonelli, M. R., & Park, D. R. (2013) · CHEST Journal · doi:10.1378/chest.12-2131 · Cited by 125
Algera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., & Olofsen, E. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.023 · Cited by 123 · cited 2×
“Algera et al. [89] reviewed human studies on reversal using models that describe and predict the time course 100% between individuals but also is usually reproduced in an individual.”
BackgroundTreatment of overdose in the synthetic opioid era
Skolnick, P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108019 · Cited by 120
Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review
Kim, H. K., & Nelson, L. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1037274 · Cited by 116 · cited 2×
“Yassen et al. (see “Pharmacometric studies” section below) demonstrated a biophase equilibration half-life of buprenorphine of 173 min [15], while Kim et al. reported receptor dissociation half-lives ( k off ) of 41–68 min for buprenorphine and 6.8 min for fentanyl, respectively [40].”
BackgroundInfluentialKrieter, P., Chiang, N., Gyaw, S., Skolnick, P., Crystal, R., Keegan, F., Aker, J., Beck, M., & Harris, J. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.759 · Cited by 111
Neale, J., & Strang, J. (2015) · Addiction · doi:10.1111/add.13027 · Cited by 109
Self-citationNo Deaths Associated with Patient Refusal of Transport After Naloxone-Reversed Opioid Overdose
Wampler, D. A., Molina, D. K., McManus, J., Laws, P., & Manifold, C. A. (2011) · Prehospital Emergency Care · doi:10.3109/10903127.2011.569854 · Cited by 105
Robertson, T. M., Hendey, G. W., Stroh, G., & Shalit, M. (2009) · Prehospital Emergency Care · doi:10.1080/10903120903144866 · Cited by 105
Yassen, A., Olofsen, E., Romberg, R., Sarton, E., Teppema, L., Danhof, M., & Dahan, A. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100025 · Cited by 105
Dowling, J., Isbister, G. K., Kirkpatrick, C. M. J., Naidoo, D., & Graudins, A. (2008) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e3181816214 · Cited by 102
The toxicology of heroin-related death: estimating survival times
Darke, S. G., & Duflou, J. A. (2016) · Addiction · doi:10.1111/add.13429 · Cited by 102
Kienbaum, P., Thurauf, N., Michel, M. C., Scherbaum, N., Gastpar, M., & Peters, J. (1998) · Anesthesiology · doi:10.1097/00000542-199805000-00004 · Cited by 100
Poklis, J. L., Poklis, A., Wolf, C. E., Mainland, M., Hair, L. S., Devers, K. G., Chrostowski, L., Arbefeville, E. F., Merves, M. L., & Pearson, J. M. (2015) · Forensic Science International · doi:10.1016/j.forsciint.2015.10.021 · Cited by 98
Low absolute bioavailability of oral naloxone in healthy subjects
Smith, K., Hopp, M., Mundin, G., Bond, S., Bailey, P., Woodward, J., & Bell, D. (2012) · Int. Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp201646 · Cited by 97
McDonald, R., Lorch, U., Woodward, J., Bosse, B., Dooner, H., Mundin, G., Smith, K., & Strang, J. (2018) · Addiction · doi:10.1111/add.14033 · Cited by 97
Self-citationComparison of Potency and Duration of Action of Nalmefene and Naloxone
Glass, P. S. A., Jhaveri, R. M., & Smith, L. R. (1994) · Anesthesia & Analgesia · doi:10.1213/00000539-199403000-00021 · Cited by 94
Acute Pulmonary Edema in Healthy Teenagers Following Conservative Doses of Intravenous Naloxone
Prough, D. S., Roy, R. C., Bumgarner, J., & Shannon, G. (1984) · Anesthesiology · doi:10.1097/00000542-198405000-00018 · Cited by 91
Vilke, G. M., Sloane, C., Smith, A. M., & Chan, T. C. (2003) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2003.tb00636.x · Cited by 89
Gottås, A., Øiestad, E. L., Boix, F., Vindenes, V., Ripel, Å., Thaulow, C. H., & Mørland, J. G. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12305 · Cited by 87
BEHAVIOURAL EFFECTS AFTER HIGH DOSE NALOXONE ADMINISTRATION TO NORMAL VOLUNTEERS
Cohen, M. R., Cohen, R. M., Pickar, D., Weingartner, H., Murphy, D., & Bunney, W. (1981) · The Lancet · doi:10.1016/s0140-6736(81)91308-8 · Cited by 81
Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial
Dietze, P., JAUNCEY, M. E., Salmon, A. M., Mohebbi, M., Latimer, J., van Beek, I., McGrath, C., & Kerr, D. C. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.14977 · Cited by 79
Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., & Walsh, S. L. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03424.x · Cited by 77
Foldes, F. F., LUNN, J. N., MOORE, J., & Brown, I. M. (1963) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196301000-00003 · Cited by 77
[3H]Alvimopan binding to the μ opioid receptor: Comparative binding kinetics of opioid antagonists
Cassel, J. A., Daubert, J. D., & DeHaven, R. N. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.08.008 · Cited by 74
Olofsen, E., van Dorp, E., Teppema, L., Aarts, L., Smith, T. W., Dahan, A., & Sarton, E. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181d5e29d · Cited by 72
Foldes, F. F., Duncalf, D., & Kuwabara, S. (1969) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03005795 · Cited by 70
Continuous Infusion of Naloxone in the Treatment of Narcotic Overdose
Bradberry, J. C., & Raebel, M. A. (1981) · Drug Intelligence & Clinical Pharmacy · doi:10.1177/106002808101501205 · Cited by 68 · cited 1×
“An infusion rate of 2.5 μg/kg/h for 12 and 30 h, respectively, successfully restored respiration in both [68].”
MethodInfluentialPhysiological effects of high dose naloxone administration to normal adults
Cohen, M. R., Cohen, R. M., Pickar, D., Murphy, D. L., & Bunney, W. E. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90443-x · Cited by 66
Nasal Administration of Naloxone Is as Effective as the Intravenous Route in Opiate Addicts
Loimer, N., Hofmann, P., & Chaudhry, H. R. (1994) · International Journal of the Addictions · doi:10.3109/10826089409047912 · Cited by 66
Kim, S., Wagner, H. N., Vl, V., Pf, K., Dannals, R. F., Ravert, H. T., Joh, T. H., Rb, D., & Ac, C. (1997) · PubMed · Cited by 65
Rapid widespread distribution of intranasal naloxone for overdose prevention
Eide, D., Clausen, T., & Lobmaier, P. P. K. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.12.013 · Cited by 62
Pulmonary Complications of Opioid Overdose Treated With Naloxone
Farkas, A., Lynch, M. J., Westover, R., Giles, J., Siripong, N., Nalatwad, A., Pizon, A. F., & Martin-Gill, C. (2020) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.04.006 · Cited by 61
Intranasal naloxone rapidly occupies brain mu-opioid receptors in human subjects
Johansson, J. J., Hirvonen, J., Lovró, Z., Ekblad, L. L., Kaasinen, V., Rajasilta, O., Helin, S., Tuisku, J., Sirén, S., Pennanen, M., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0368-x · Cited by 60
Opioid Toxicity Recurrence After an Initial Response to Naloxone
Watson, W. A., Steele, M. T., Muelleman, R. L., & Rush, M. D. (1998) · Journal of Toxicology Clinical Toxicology · doi:10.3109/15563659809162577 · Cited by 58
New and Experimental Therapeutic Roles for Naloxone and Related Opioid Antagonists
McNicholas, L. F., & Martin, W. R. (1984) · Drugs · doi:10.2165/00003495-198427010-00004 · Cited by 56
Recurrent opioid toxicity after pre‐hospital care of presumed heroin overdose patients
Boyd, J. J., Kuisma, M. J., Alaspää, A. O., Vuori, E., Repo, J. V., & Randell, T. T. (2006) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.2006.01172.x · Cited by 55
Strang, J., McDonald, R., Alqurshi, A. A., Royall, P. G., Taylor, D. M., & Forbes, B. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.042 · Cited by 54
Self-citationValbrun, L., & Zvonarev, V. (2020) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4066 · Cited by 54
Mann, J., Samieegohar, M., Chaturbedi, A., Zirkle, J., Han, X., Ahmadi, S. F., Eshleman, A., Janowsky, A., Wolfrum, K., Swanson, T., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2696 · Cited by 54
Naloxone therapy in opioid overdose patients: Intranasal or intravenous? A randomized clinical trial
Sabzghabaee, A. M., Eizadi-Mood, N., Yaraghi, A., & Zandifar, S. (2014) · Archives of Medical Science · doi:10.5114/aoms.2014.42584 · Cited by 53 · cited 2×
“Nasal naloxone has been compared with intravenous [151] or intramuscular naloxone in five randomized controlled studies of opioid overdoses (see Supplementary Information for details).”
BackgroundMethodCounteraction of Narcotic Antagonist Analgesics by the Narcotic Antagonist Naloxone
Blumberg, H., Dayton, H. B., & Wolf, P. S. (1966) · Experimental Biology and Medicine · doi:10.3181/00379727-123-31595 · Cited by 53
Moss, R. B., Pryor, M. M., Baillie, R., Kudrycki, K., Friedrich, C. M., Reed, M., & Carlo, D. J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234683 · Cited by 51
Miner, N. B., Schutzer, W. E., Zarnegarnia, Y., Janowsky, A. J., & Torralva, R. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108974 · Cited by 51
Prehospital treatment of opioid overdose in Copenhagen—Is it safe to discharge on-scene?
Rudolph, S. S., Jehu, G. T., Loumann-Nielsen, S., Nielsen, K., Siersma, V., & Rasmussen, L. S. (2011) · Resuscitation · doi:10.1016/j.resuscitation.2011.06.027 · Cited by 50
Trøstheim, M., Eikemo, M., Haaker, J., Frost, J. J., & Leknes, S. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01416-z · Cited by 49
Naloxone displacement at opioid receptor sites measured in vivo in the human brain
Melichar, J., Nutt, D., & Malizia, A. L. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)02872-8 · Cited by 48
Skulberg, A. K., Tylleskär, I., Valberg, M., Braarud, A., Dale, J., Heyerdahl, F., Skålhegg, T., Barstein, J., Mellesmo, S., & Dale, O. (2022) · Addiction · doi:10.1111/add.15806 · Cited by 46
Self-citationNaloxone dosing in the era of ultra-potent opioid overdoses: a systematic review
Moe, J., Godwin, J., Purssell, R., O'Sullivan, F., Hau, J. P., Purssell, E., Curran, J., Doyle-Waters, M. M., Brasher, P. M. A., Buxton, J. A., et al. (2020) · CJEM · doi:10.1017/cem.2019.471 · Cited by 45
Nasal administration of naloxone for detection of opiate dependence
Loimer, N., Hofmann, P. J., & Chaudhry, H. R. (1992) · Journal of Psychiatric Research · doi:10.1016/0022-3956(92)90014-f · Cited by 44
Pharmacokinetics of a new, nasal formulation of naloxone
Tylleskär, I., Skulberg, A. K., Nilsen, T., Skarra, S., Jansook, P., & Dale, O. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2191-1 · Cited by 43
Self-citationIntranasal midazolam: a comparison of two delivery devices in human volunteers
Dale, O., Nilsen, T., Loftsson, T., Tønnesen, H. H., Klepstad, P., Kaasa, S., Holand, T., & Djupesland, P. G. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.10.0003 · Cited by 42
Self-citationComparative Usability Study of a Novel Auto-Injector and an Intranasal System for Naloxone Delivery
Edwards, E. T., Edwards, E. S., Davis, E., Mulcare, M., Wiklund, M., & Kelley, G. G. (2015) · Pain and Therapy · doi:10.1007/s40122-015-0035-9 · Cited by 42
Strang, J., McDonald, R., Tas, B., & Day, E. (2016) · Addiction · doi:10.1111/add.13209 · Cited by 42
Self-citationNaloxone-Associated Patient Violence: An Overlooked Toxicity?
Gaddis, G., & Watson, W. A. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202600211 · Cited by 42
Illicit Fentanyl-Related Fatalities in Florida: Toxicological Findings
Lee, D., Chronister, C. W., Broussard, W. A., Utley, S. R., Schultz, D. L., Vega, R. S., & Goldberger, B. A. (2016) · Journal of Analytical Toxicology · doi:10.1093/jat/bkw087 · Cited by 42
Pharmacotherapy for dissociative disorders: A systematic review
Sutar, R., & Sahu, S. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112529 · Cited by 42
Morlion, B. J., Mueller‐Lissner, S. A., Vellucci, R., Leppert, W., Coffin, B. C., Dickerson, S. L., & O'Brien, T. (2018) · Pain Practice · doi:10.1111/papr.12646 · Cited by 41
Avetian, G. K., Fiuty, P., Mazzella, S., Koppa, D., Heye, V., & Hebbar, P. B. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1334637 · Cited by 40
Interaction With the Lipid Membrane Influences Fentanyl Pharmacology
Sutcliffe, K. J., Corey, R. A., Alhosan, N., Cavallo, D., Groom, S., Santiago, M., Bailey, C., Charlton, S. J., Sessions, R. B., Henderson, G., et al. (2022) · Advances in Drug and Alcohol Research · doi:10.3389/adar.2022.10280 · Cited by 39
Gourlay, G. K., & Coulthard, K. P. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01498.x · Cited by 37
Albeck, H., Woodfield, S., & Kreek, M. J. (1989) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)82967-9 · Cited by 35
Kanemasa, T., Koike, K., Takase, K., Arai, T., Nakamura, A., Morioka, Y., & Hasegawa, M. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.264515 · Cited by 35
Metabolism and pharmacokinetics of naloxone.
Weinstein, S. H., Pfeffer, M., & Schor, J. M. (1973) · PubMed · Cited by 32
Moustaqim‐Barrette, A., Papamihali, K., Williams, S., Ferguson, M., Moe, J., Purssell, R. A., & Buxton, J. A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259126 · Cited by 32
Methadone Overdose Treated With Naloxone Infusion
Waldron, V. D. (1973) · JAMA · doi:10.1001/jama.1973.03220280041012 · Cited by 31
Krieter, P. A., Chiang, C. N., Gyaw, S., & McCann, D. J. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1401 · Cited by 31
Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic
Balyan, R., Hahn, D., Huang, H. D., & Chidambaran, V. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1721458 · Cited by 31
Continuous Naloxone Infusion in Pediatric Narcotic Overdose
Lewis, J. M. (1984) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/archpedi.1984.02140480046014 · Cited by 30
Isolation of Naloxone-3-glucuronide from Human Urine
Fujimoto, J. M. (1970) · Experimental Biology and Medicine · doi:10.3181/00379727-133-34465 · Cited by 29
Eide, D., Skulberg, A. K., Braarud, A., Dale, O., Heyerdahl, F., Lobmaier, P. P. K., & Clausen, T. (2018) · Substance Abuse · doi:10.1080/08897077.2018.1485130 · Cited by 28
Self-citationTakahashi, M., Sugiyama, K., Hori, M., Chiba, S., & 日下, 潔. (2004) · Journal of Anesthesia · doi:10.1007/s00540-003-0214-4 · Cited by 27
Friedman, M. S., & Manini, A. F. (2016) · Journal of Medical Toxicology · doi:10.1007/s13181-016-0549-5 · Cited by 27
Pulmonary edema following naloxone administration in a healthy orthopedic patient
Johnson, C. W., Mayer, P., & Grosz, D. (1995) · Journal of Clinical Anesthesia · doi:10.1016/0952-8180(95)00038-j · Cited by 26
Partial versus full agonists for opioid-mediated analgesia--focus on fentanyl and buprenorphine.
Zuurmond, W. W. A., Meert, T. F., & Noorduin, H. (2002) · PubMed · Cited by 25
Simplified detection system for neuroreceptor studies in the human brain.
Bice, A. N., Wagner, H. N., Frost, J. J., Natarajan, T. K., Lee, M. C., Wong, D. F., Dannals, R. F., Ravert, H. T., Wilson, A. A., & Links, J. M. (1986) · PubMed · Cited by 25
Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
Colucci, S. V., Perrino, P. J., Shram, M. J., Bartlett, C., Wang, Y., & Harris, S. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0192-3 · Cited by 25
Prehospital naloxone administration – what influences choice of dose and route of administration?
Tylleskär, I., Gjersing, L., Bjørnsen, L. P., Braarud, A., Heyerdahl, F., Dale, O., & Skulberg, A. K. (2020) · BMC Emergency Medicine · doi:10.1186/s12873-020-00366-3 · Cited by 25
Self-citationSystematic Review of Naloxone Dosing and Adverse Events in the Emergency Department
Yugar, B., McManus, K., Ramdin, C., Nelson, L. S., & Parris, M. A. (2023) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2023.05.006 · Cited by 25
Skulberg, A. K., Åsberg, A., Zaré, H. K., Røstad, H., Tylleskär, I., & Dale, O. (2019) · Addiction · doi:10.1111/add.14552 · Cited by 24
Self-citationSentanyl: a comparison of blood fentanyl concentrations and naloxone dosing after non-fatal overdose
Krotulski, A. J., Chapman, B. P., Marks, S. J., Ontiveros, S. T., Devin-Holcombe, K., Fogarty, M. F., Trieu, H., Logan, B. K., Merchant, R. C., & Babu, K. M. (2022) · Clinical Toxicology · doi:10.1080/15563650.2021.1948558 · Cited by 24
Naloxone-associated pulmonary edema following recreational opioid overdose
Kummer, R. L., Kempainen, R. R., Olives, T. D., Leatherman, J. W., & Prekker, M. E. (2021) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2021.12.030 · Cited by 23
Naloxone for opiate-exposed newborn infants
Moe‐Byrne, T., Brown, J. V. E., & McGuire, W. L. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003483.pub2 · Cited by 22
Skulberg, A. K., Tylleskär, I., Nilsen, T., Skarra, S., Salvesen, Ø. O., Sand, T., Loftsson, Þ., & Dale, O. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2443-3 · Cited by 21
Self-citationNaloxone for opioid-exposed newborn infants
Moe‐Byrne, T., Brown, J. V. E., & McGuire, W. L. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003483.pub3 · Cited by 19
Naloxone induced pulmonary edema
Elkattawy, S., Alyacoub, R., EJIKEME, C. P., Noori, M. A. M., & Remolina, C. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2020.1854417 · Cited by 19
Isoardi, K., Parker, L., Harris, K., Rashford, S., & Isbister, G. K. (2022) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.03.004 · Cited by 19
A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose
Lapidot, T., Bouhajib, M., Faulknor, J., Khan, S., Krayz, G. T., Abrutzky, C., & Megiddo, D. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03247-5 · Cited by 18
Pharmacokinetics after a single dose of naloxone administered as a nasal spray in healthy volunteers
Vanky, E., Hellmundt, L., Bondesson, U., Eksborg, S., & Lundeberg, S. (2017) · Acta Anaesthesiologica Scandinavica · doi:10.1111/aas.12898 · Cited by 17
Olofsen, E., Mooren, R. A. G., van Dorp, E., Aarts, L. P. H. J., Smith, T., den Hartigh, J., Dahan, A., & Sarton, E. Y. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181e5e8af · Cited by 16
Alqurshi, A. A., Kumar, Z., McDonald, R., Strang, J., Buanz, A. B. M., Ahmed, S., Allen, E. M., Cameron, P., Rickard, J. A., Sandhu, V., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00096 · Cited by 16
Self-citationToxicity: exploring and expanding the concept
Strang, J., Neale, J., McDonald, R., & Kalk, N. J. (2017) · Addiction · doi:10.1111/add.14080 · Cited by 16
Self-citationPharmacokinetics of Tilidine and Naloxone in Patients with Severe Hepatic Impairment
Brennscheidt, U., Brunnmüller, U., Proppe, D., Thomann, P. E., & Seiler, K. (2011) · Arzneimittelforschung · doi:10.1055/s-0031-1296591 · Cited by 15
Gufford, B. T., Ainslie, G. R., White, J. R., Layton, M. E., Padowski, J. M., Pollack, G. M., & Paine, M. (2017) · Clinical and Translational Science · doi:10.1111/cts.12473 · Cited by 15
McDonald, R., Glende, Ø. D., Dale, O., & Strang, J. (2017) · Drug and Alcohol Review · doi:10.1111/dar.12571 · Cited by 15
Self-citationRavnborg, M. H., Jensen, F. M., Jensen, N., & Holk, I. K. (1987) · Anesthesia & Analgesia · doi:10.1213/00000539-198709000-00007 · Cited by 14
Villemagne, V. L., Frost, J. J., Dannals, R. F., Lever, J. R., Tanada, S., Natarajan, T. K., Wilson, A. A., Ravert, H. T., & Wagner, H. N. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90712-9 · Cited by 14
WALSH, S. L., Nuzzo, P. A., Babalonis, S. L., Casselton, V., & Lofwall, M. R. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.03.005 · Cited by 14
Tylleskär, I., Skulberg, A. K., Skarra, S., Nilsen, T., & Dale, O. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2545-y · Cited by 13
Self-citationThe effects of heat and freeze-thaw cycling on naloxone stability
Lai, D., Pham, A. T., Rao, P. P. N., & Beazely, M. A. (2019) · Harm Reduction Journal · doi:10.1186/s12954-019-0288-4 · Cited by 13
Tigerstedt, I., & Tammisto, T. (1978) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1978.tb01293.x · Cited by 12
High-dose naloxone, an experimental tool uncovering latent sensitisation: pharmacokinetics in humans
Papathanasiou, T., Springborg, A. H., Kongstad, K. T., Stærk, D., Møller, K., Taylor, B. K., Lund, T. M., & Werner, M. U. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.007 · Cited by 12
Rapid systemic uptake of naloxone after intranasal administration in children
Olsson, E. M., Lönnqvist, P., Stiller, C., Eksborg, S., & Lundeberg, S. (2021) · Pediatric Anesthesia · doi:10.1111/pan.14175 · Cited by 12
Dale, O. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2072728 · Cited by 12
Self-citationEthical issues and stakeholders matter
Dale, O. (2016) · Addiction · doi:10.1111/add.13267 · Cited by 11
Self-citationSpringborg, A. H., Jensen, E. K., Kreilgaard, M., Petersen, M. A., Papathanasiou, T., Lund, T. M., Taylor, B. K., & Werner, M. U. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242169 · Cited by 11
Strang, J. (2021) · European Addiction Research · doi:10.1159/000519939 · Cited by 11
Self-citationOutcomes of law enforcement officer administered naloxone
Gooley, B., Weston, B., Colella, M. R., & Farkas, A. (2022) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2022.09.041 · Cited by 11 · cited 2×
“Suspected fentanyl exposure, suspected benzodiazepine exposure, and higher doses of naloxone were associated with more frequent withdrawal symptoms [143].”
BackgroundSadzot, B., Hs, M., & Jj, F. (1990) · PubMed · Cited by 10
Naloxone‐associated pulmonary edema in a 3‐year‐old with opioid overdose
Grout, S. E., Dave, M., & Lefort, R. (2022) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12740 · Cited by 10
Stam, N. C., Cogger, S., Schumann, J., Weeks, A., Roxburgh, A., Dietze, P., & Clark, N. C. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2126371 · Cited by 10
Naloxone nasal spray – bioavailability and absorption pattern in a phase 1 study
Tylleskär, I., Skulberg, A. K., Nilsen, T., Skarra, S., & Dale, O. (2019) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.19.0162 · Cited by 9
Self-citationThompson, J. (2021) · Deep Blue (University of Michigan) · doi:10.7302/3593 · Cited by 9
Thompson, J., Salter, J., Bui, P. V., Herbert, L., Mills, D., Wagner, D., & Brent, C. M. (2021) · Annals of Pharmacotherapy · doi:10.1177/10600280211030918 · Cited by 9
High-potency benzodiazepine misuse in opioid-dependent patients: use naloxone with care
Raman, R. (2022) · Emergency Medicine Journal · doi:10.1136/emermed-2021-212254 · Cited by 7
Tylleskär, I., Skarra, S., Skulberg, A. K., & Dale, O. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03190-1 · Cited by 6
Self-citationNaloxone Dosing in the Era of Fentanyl: The Path Widens by Traveling Down It
Wightman, R., & Nelson, L. S. (2022) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2022.04.014 · Cited by 6
Tsekouras, A. A., & Macheras, P. E. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00831-x · Cited by 5
Naloxone administration—no balance without titration
Skulberg, A. K., Tylleskär, I., & Dale, O. (2022) · Addiction · doi:10.1111/add.15947 · Cited by 1
Self-citation
Research works printed but not linked: 6
- Garfield E. The 1982 John Scott Award goes to Jack Fishman and Harold Blumberg for synthesis and investigations on naloxone. Essay Inf Sci. 1983;6:121–30.
- Blumberg H, Dayton HB, George M, Rapaport DN. N-allylnoroxynorphone; a potent narcotic antagonist. Fedn Proc Fedn Am Soc. 1961;20:311.
- Naloxone. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Naloxone#section=3D-Conformer. Accessed Oct 26 2022.
- World Health Organization, Management of Substance Abuse Team. Community management of opioid overdose. Geneva: World Health Organization; 2014.
- Lemen PM, Garrett DP, Thompson E, Aho M, Vasquez C, Park JN. High-dose naloxone formulations are not as essential as we thought. medRxiv. 2023;6:63.
- World Health Organization. WHO guidelines approved by the guidelines. Review committee community management of opioid overdose. Geneva: World Health Organization; 2014.
Cited by
Nitazenes: review of comparative pharmacology and antagonist action
Stangeland, M., Dale, O., & Skulberg, A. K. (2025) · Clinical Toxicology · doi:10.1080/15563650.2025.2504133 · Cited by 34
Self-citationA call for compassionate opioid overdose response
Russell, E., Hawk, M., Neale, J., Bennett, A. S., Davis, C., Hill, L. G., Winograd, R., Kestner, L., Lieberman, A., Bell, A., et al. (2024) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2024.104587 · Cited by 28
Stevens, A., Keemink, J. R., Shirley‐Beavan, S., Khadjesari, Z., Artenie, A. A., Vickerman, P. T., Southwell, M., & Shorter, G. W. (2024) · Drug and Alcohol Review · doi:10.1111/dar.13908 · Cited by 27
Synthetic opioids have disrupted conventional wisdom for treating opioid overdose
Skolnick, P., Paavola, J., & Heidbreder, C. A. (2024) · Drug and Alcohol Dependence Reports · doi:10.1016/j.dadr.2024.100268 · Cited by 19
Naloxone dosing in the era of synthetic opioids: Applying the Goldilocks principle
Utrilla, M. G., Chesney, E., Neale, J., Metrebian, N., Kalk, N. J., Skulberg, A. K., Dietze, P., Smith, M. P., & Strang, J. (2025) · Addiction · doi:10.1111/add.70060 · Cited by 16
Self-citation
Metadata
- Authors
- Saari, T. I., Strang, J., & Dale, O.
- Affiliations
- University of Turku (FI)
- King's College London (GB)
- Norwegian University of Science and Technology (NO)
- Corresponding author
- Dale, Ola
- Venue
- Clinical Pharmacokinetics
- Published
- 2024-03-14
- Volume
- 63
- Issue
- 4
- Pages
- 397-422
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC11052794
- OpenAlex
- W4392796714
- Cited by
- 77
- References
- 154
- Citations by year
- 2026: 41 · 2025: 29 · 2024: 7
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- UTUPub (University of Turku) (submittedVersion, cc-by-nc)
- Funders
- NTNU Norwegian University of Science and Technology
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- naloxone, opioid overdose, respiratory depression, mu-opioid receptor, pharmacokinetics, pharmacodynamics, intranasal administration, take-home naloxone, heroin overdose, fentanyl overdose, pharmacokinetic variability
- MeSH terms
- Administration, Intranasal, Analgesics, Opioid, Animals, Half-Life, Humans, Naloxone, Narcotic Antagonists, Drug Overdose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.